Antithymocyte globulin-induced hemolytic anemia and thrombocytopenia after kidney transplantation - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Immunotherapy Année : 2018

Antithymocyte globulin-induced hemolytic anemia and thrombocytopenia after kidney transplantation

Résumé

Antithymocyte globulin is the most widely used lymphocyte-depleting treatment in kidney transplantation. In spite of the frequency of side effects, including anemia and thrombocytopenia, their pathophysiological mechanisms are not clearly established. Here, we report the case of a 21-year-old patient who had a first kidney transplantation and received induction immunosuppressive therapy by thymoglobulin. Immediately after kidney transplantation, he developed a severe hemolytic anemia and thrombocytopenia with a subsequent perirenal hematoma, which lead to a second surgical procedure and a transfer to the intensive care unit. Our patients' anemia and thrombocytopenia had heteroimmune characteristics, and thymoglobulin therapy was suspected to be the cause, via an interaction with a common Fc-receptor epitope in the different cell lines.
Fichier non déposé

Dates et versions

inserm-02454015 , version 1 (24-01-2020)

Identifiants

Citer

T de Nattes, L Lelandais, I Etienne, C Laurent, Dominique Guerrot, et al.. Antithymocyte globulin-induced hemolytic anemia and thrombocytopenia after kidney transplantation. Immunotherapy, 2018, 10 (9), pp.737-742. ⟨10.2217/imt-2017-0135⟩. ⟨inserm-02454015⟩
59 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More